Pharmacokinetic III Dr Hayder B Sahib Ph D

Pharmacokinetic III Dr. Hayder B Sahib Ph. D. , MSc. , DSc, BSc Pharm.

VI. DRUG CLEARANCE BY THE KIDNEY • A. Renal elimination of a drug • Elimination of drugs via the kidneys into urine involves the processes of • 1 - glomerular filtration • 2 - active tubular secretion • 3 - passive tubular reabsorption. • 1. Glomerular filtration: Drugs enter the kidney through renal arteries, which divide to form a glomerular capillary plexus. • Free drug (not bound to albumin) flows through the capillary slits into the Bowman space as part of the glomerular filtrate. • The glomerular filtration rate (GFR) is normally about 125 m. L/min but may diminish significantly in renal disease.

• Lipid solubility and p. H do not influence the passage of drugs into the glomerular filtrate. However, variations in GFR and protein binding of drugs do affect this process. • 2. Proximal tubular secretion: Drugs that were not transferred into the glomerular filtrate leave the glomeruli through efferent arterioles, which divide to form a capillary plexus surrounding the nephric lumen in the proximal tubule. • Secretion primarily occurs in the proximal tubules by two energy-requiring active transport systems: • 1 - one for anions (for example, deprotonated forms of weak acids) • 2 - one for cations (for example, protonated forms of weak bases).

• Each of these transport systems shows low specificity and can transport many compounds. Thus, competition between drugs for these carriers can occur within each transport system. • [Note: Premature infants and neonates have an incompletely developed tubular secretory mechanism and, thus, may retain certain drugs in the glomerular filtrate. ] do this elucidate the drug monitoring

• 3. Distal tubular reabsorption: As a drug moves toward the distal convoluted tubule, its concentration increases and exceeds that of the perivascular space. • The drug, if uncharged, may diffuse out of the nephric lumen, back into the systemic circulation. • Manipulating the urine p. H to increase the fraction of ionized drug in the lumen may be done to minimize the amount of back diffusion and increase the clearance of an undesirable drug. • As a general rule, weak acids can be eliminated by alkalinization of the urine, whereas elimination of weak bases may be increased by acidification of the urine. • This process is called “ion trapping. ” For example, a patient presenting with phenobarbital (weak acid) overdose can be given bicarbonate, which alkalinizes the urine and keeps the drug ionized, thereby decreasing its reabsorption.

• 4. Role of drug metabolism: Most drugs are lipid soluble and, without chemical modification, would diffuse out of the tubular lumen when the drug concentration in the filtrate becomes greater than that in the perivascular space. • To minimize this reabsorption, drugs are modified primarily in the liver into more polar substances via phase I and phase II reactions (described above). • The polar or ionized conjugates are unable to back diffuse out of the kidney lumen

VII. CLEARANCE BY OTHER ROUTES • • • Drug clearance may also occur via 1 - the intestines 2 - bile 3 - lungs 4 - breast milk Drugs that are not absorbed after oral administration or drugs that are secreted directly into the intestines or into bile are eliminated in the feces. • The lungs are primarily involved in the elimination of anesthetic gases (for example, isoflurane).

• Elimination of drugs in breast milk may expose the breast-feeding infant to medications and/or metabolites being taken by the mother and is a potential source of undesirable side effects to the infant. • Excretion of most drugs into sweat, saliva, tears, hair, and skin occurs only to a small extent. • Total body clearance and drug half-life are important measures of drug clearance that are used to optimize drug therapy and minimize toxicity

• A. Total body clearance • The total body (systemic) clearance, CL total, is the sum of all clearances from the drug-metabolizing and drug-eliminating organs. • The kidney is often the major organ of elimination. • The liver also contributes to drug clearance through metabolism and/or excretion into the bile. • Total clearance is calculated using the following equation: • CL total= CL hepatic +Cl renal+ CL pulmonary+ CL other where CL hepatic + CL renal are typically the most important.

• B. Clinical situations resulting in changes in drug half-life • When a patient has an abnormality that alters the half-life of a drug, adjustment in dosage is required. • Patients who may have an increase in drug half-life include those with • 1) diminished renal or hepatic blood flow, for example, in cardiogenic shock, heart failure, or hemorrhage • 2) decreased ability to extract drug from plasma, for example, in renal disease • 3) decreased metabolism, for example, when a concomitant drug inhibits metabolism or in hepatic insufficiency, as with cirrhosis. • These patients may require a decrease in dosage or less frequent dosing intervals. .

• • The half-life of a drug may be decreased by 1 - increased hepatic blood flow 2 - decreased protein binding 3 - increased metabolism. • This may necessitate higher doses or more frequent dosing intervals

VIII. DESIGN AND OPTIMIZATION OF DOSAGE REGIMEN • • To initiate drug therapy, the clinician must select 1 - the appropriate route of administration 2 - dosage 3 - dosing interval • Selection of a regimen depends on various patient and drug factors, including how rapidly therapeutic levels of a drug must be achieved. • The regimen is then further refined, or optimized, to maximize benefit and minimize adverse effects.

Continuous infusion regimens • Therapy may consist of a single dose of a drug, for example, a sleep inducing agent, such as zolpidem. • More commonly, drugs are continually administered, either as an IV infusion or in oral fixed-dose/ fixed-time interval regimens (for example, “one tablet every 4 hours”). • Continuous or repeated administration results in accumulation of the drug until a steady state occurs. • Steady-state concentration is reached when the rate of drug elimination is equal to the rate of drug administration, such that the plasma and tissue levels remain relatively constant.

• 1. Plasma concentration of a drug following IV infusion: • With continuous IV infusion, the rate of drug entry into the body is constant. • Most drugs exhibit first-order elimination, that is, a constant fraction of the drug is cleared per unit of time. Therefore, the rate of drug elimination increases proportionately as the plasma concentration increases. • Following initiation of a continuous IV infusion, the plasma concentration of a drug rises until a steady state (rate of drug elimination equals rate of drug administration) is reached, at which point the plasma concentration of the drug remains constant

• a. Influence of the rate of infusion on steady-state concentration: • The steady-state plasma concentration (Css) is directly proportional to the infusion rate. • Css is inversely proportional to the clearance of the drug. • Thus, any factor that decreases clearance, such as liver or kidney disease, increases the Css of an infused drug (assuming Vd remains constant). • Factors that increase clearance, such as increased metabolism, decrease the Css.

b. Time required to reach the steady-state drug concentration: • The concentration of a drug rises from zero at the start of the infusion to its ultimate steady-state level, Css • The rate constant for attainment of steady state is the rate constant for total body elimination of the drug. • Thus, 50% of Css of a drug is observed after the time elapsed, since the infusion, t, is equal to t 1/2, where t 1/2 (or half-life) is the time required for the drug concentration to change by 50%. • After another half-life, the drug concentration approaches 75% of Css. • The drug concentration is 87. 5% of Css at 3 half-lives and 90% at 3. 3 half-lives. Thus, a drug reaches steady state in about four to five half-lives

• The sole determinant of the rate that a drug achieves steady state is the half-life (t 1/2) of the drug, and this rate is influenced only by factors that affect the half-life. • The rate of approach to steady state is not affected by the rate of drug infusion. • When the infusion is stopped, the plasma concentration of a drug declines (washes out) to zero with the same time course observed in approaching the steady state

B. Fixed-dose/fixed-time regimens • Administration of a drug by fixed doses rather than by continuous infusion is often more convenient. • However, fixed doses of IV or oral medications given at fixed intervals result in time-dependent fluctuations in the circulating level of drug, which contrasts with the smooth rise of drug concentration observed with continuous infusion. • 1. Multiple IV injections: When a drug is given repeatedly at regular intervals, the plasma concentration increases until a steady state is reached.

• Because most drugs are given at intervals shorter than five half-lives and are eliminated exponentially with time, some drug from the first dose remains in the body when the second dose is administered, some from the second dose remains when the third dose is given, and so forth. • Therefore, the drug accumulates until, within the dosing interval, the rate of drug elimination equals the rate of drug administration and a steady state is achieved.

• a. Effect of dosing frequency: • With repeated administration at regular intervals, the plasma concentration of a drug oscillates about a mean. • Using smaller doses at shorter intervals reduces the amplitude of fluctuations in drug concentration. • However, the Css is affected by neither the dosing frequency (assuming the same total daily dose is administered) nor the rate at which the steady state is approached.

. Multiple oral administrations: • Most drugs that are administered on an outpatient basis are oral medications taken at a specific dose one, two, or three times daily. • In contrast to IV injection, orally administered drugs may be absorbed slowly, and the plasma concentration of the drug is influenced by both the rate of absorption and the rate of elimination

• C. Optimization of dose • The goal of drug therapy is to achieve and maintain concentrations within a therapeutic response window while minimizing toxicity and/ or side effects. • If therapeutic window of the drug is small (for example, digoxin, warfarin, and cyclosporine), extra caution should be taken in selecting a dosage regimen, and monitoring of drug levels may help ensure attainment of therapeutic range. • Drug regimens are administered as a maintenance dose and may require a loading dose if rapid effects are warranted. • For drugs with a defined therapeutic range, drug concentrations are subsequently measured, and the dosage and frequency are then adjusted to obtain the desired levels.

• 1. Maintenance dose: • Drugs are generally administered to maintain a Css within therapeutic window. • It takes four to five half-lives for a drug to achieve Css. • To achieve a given concentration the rate of administration and the rate of elimination of the drug are important. • The dosing rate can be determined by knowing • 1 - the target concentration in plasma (Cp) • 2 - clearance (CL) of the drug from the systemic circulation • 3 - the fraction (F) absorbed (bioavailability):

• Dosing rate= target plasma conc. X CL F

• 2. Loading dose: Sometimes rapid obtainment of desired plasma levels is needed (for example, in serious infections or arrhythmias). • Therefore, a “loading dose” of drug is administered to achieve the desired plasma level rapidly, followed by a maintenance dose to maintain the steady stat • Loading dose = (Vd) × (desired steady-state plasma concentration)/F • For IV infusion, the bioavailability is 100%,

• and the equation becomes • Loading dose = (Vd) × (desired steady-state plasma concentration) • Loading doses can be given as a single dose or a series of doses. • Disadvantages of loading doses include • 1 - increased risk of drug toxicity • 2 - longer time for the plasma concentration to fall if excess levels occur. • A loading dose is most useful for drugs that have a relatively long half-life. • Without an initial loading dose, these drugs would take a long time to reach a therapeutic value that corresponds to the steady -state level.

• 3. Dose adjustment: The amount of a drug administered for a given condition is estimated based on an “average patient. ” This approach overlooks interpatient variability in pharmacokinetic parameters such as clearance and Vd, which are quite significant in some cases. • Monitoring drug therapy and correlating it with clinical benefits provides another tool to individualize therapy. • When determining a dosage adjustment, Vd can be used to calculate the amount of drug needed to achieve a desired plasma concentration.

• For example, assume a heart failure patient is not well controlled due to inadequate plasma levels of digoxin. • Suppose the concentration of digoxin in the plasma is C 1 and the desired target concentration is C 2, a higher concentration. • The following calculation can be used to determine how much additional digoxin should be administered to bring the level from C 1 to C 2. • (Vd)(C 1) = Amount of drug initially in the body • (Vd)(C 2) = Amount of drug in the body needed to achieve the desired plasma concentration

• The difference between the two values is the additional dosage needed, which equals • Vd (C 2 − C 1).